A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

NCT02124850 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: Motolimod
DRUG: Cetuximab
DRUG: Nivolumab

Sponsor

Celgene